HSPA5 and breast cancer: The dietary compound isoliquiritigenin (ISL) has synergistic effects with chemotherapeutic drugs for inhibiting breast cancer stem cell proliferation and colony formation, inhibiting self-renewal and multidifferentiation abilities, and targeting GRP78 via the β-catenin/ABCG2 pathway [141].